Ro 67-7476 is a potent positive allosteric modulator of mGluR1 and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC50 of 60.1 nM. Ro 67-7476 is a potent P-ERK1/2 agonist?and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC50=163.3 nM).

Dactolisib Tosylate (BEZ235 Tosylate, NVP-BEZ 235 Tosylate) is an imidazo[4,5-c]quinoline derivative and dual inhibitor of PI3K/mTOR with IC50 values of 4, 75, 7, and 5 nM for PI3Kα, β, γ, and δ, respectively. It blocks mTORC1/mTORC2 and demonstrates potent antitumor activity in experimental cancer models.

Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase. Eflornithine is a medication for the treatment of African trypanosomiasis and excessive facial hair growth in women.

Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.

Ziresovir is a potent, selective, and orally bioavailable inhibitor of respiratory syncytial virus (RSV) fusion (F) protein with EC50 of 3 nM and highlights pharmacokinetics in animal species.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.

Gliocidin (SW106065), is a nicotinamide-mimetic prodrug that targets glioblastoma cells with an IC50 of 150 nM, by exploiting a de novo purine synthesis vulnerability via indirect inhibition of IMPDH2. It readily crosses the BBB and can be used in the treatment of all malignant brain tumors.